College of Pharmacy, Center for Pharmaceutical Research and Innovation, University of Kentucky, Lexington, KY, USA.
Division of Cardiovascular Medicine, University of Kentucky, Lexington, KY, USA.
J Antibiot (Tokyo). 2014 Mar;67(3):223-30. doi: 10.1038/ja.2013.113. Epub 2013 Nov 13.
Venturicidin C (1), a new 20-membered macrolide along with the known venturicidins A (2) and B (3) were isolated from the crude extract of the Appalachian bacterial strain Streptomyces sp. TS-2-2. Additionally, nine other known compounds namely nocardamine, dehydroxynocardamine, desmethylenylnocardamine, ferrioxamine E, adenosine, riboflavin, cyclo(D)-trans-4-OH-Pro-(D)-Phe, cyclo(D)-Pro-(D)-Phe and N-(2-phenylethyl)-acetamide were also isolated and identified. The structure of the new macrolide 1 was elucidated by the cumulative analyses of NMR spectroscopy and HR-MS data. Complete NMR assignments for the known venturicidins A (2) and B (3) are also provided, for the first time, in this report. Venturicidins A-C did not inhibit the proliferation of A549 lung cancer cell line but all displayed potent antifungal activity.
Venturicidin C(1)是一种新的 20 元大环内酯,与已知的 venturicidins A(2)和 B(3)一起从 Appalachian 细菌菌株 Streptomyces sp. TS-2-2 的粗提取物中分离出来。此外,还分离并鉴定了其他 9 种已知化合物,即诺卡胺、去羟诺卡胺、去甲烯基诺卡胺、高铁氧肟酸 E、腺苷、核黄素、环(D)-反-4-OH-Pro-(D)-苯丙氨酸、环(D)-Pro-(D)-苯丙氨酸和 N-(2-苯乙基)-乙酰胺。新大环内酯 1 的结构通过 NMR 光谱和 HR-MS 数据的累积分析阐明。本报告首次提供了已知的 venturicidins A(2)和 B(3)的完整 NMR 归属。Venturicidins A-C 对 A549 肺癌细胞系的增殖没有抑制作用,但都显示出很强的抗真菌活性。